ST2 as a Cardiovascular Risk Biomarker: From the Bench to the Bedside
ST2 as a Cardiovascular Risk Biomarker: From the Bench to the Bedside
复制标题
DOI：
10.1007/s12265-013-9459-y
复制
发表时间：
2013-08-01
影响因子：
3.4
通讯作者：
Januzzi, James L., Jr.
中科院分区：
文献类型：
--
作者：
Januzzi, James L., Jr.
ST 2是以经典的转化科学方式发现的白细胞介素（IL）-1受体家族的成员，并且以两种形式存在，跨膜受体（ST 2L）以及可溶性诱饵受体（sST 2）。ST 2的配体是IL-33，其参与减少机械应变组织中的纤维化和肥大。在体外和体内模型中，ST 2L转导IL-33的作用，而过量的sST 2或ST 2信号传导异常导致心脏肥大、纤维化和心室功能障碍。临床上，在有症状的心力衰竭（HF）患者中，sST 2浓度升高与诊断的严重程度密切相关，并有力地预测并发症风险增加，独立于其他已建立或新出现的生物标志物。sST 2检测也被证明可预测急性心肌梗死患者症状性HF的发作，而在社区受试者中，sST 2值可独立预测未来的HF、心血管疾病事件和死亡率。
ST2 is a member of the interleukin (IL)-1 receptor family discovered in a classical translational science fashion, and exists in two forms, a trans-membrane receptor (ST2L) as well as a soluble decoy receptor (sST2). The ligand of ST2 is IL-33, which is involved in reducing fibrosis and hypertrophy in mechanically strained tissues. In in vitro and in vivo models, ST2L transduces the effects of IL-33, while excess sST2 or abnormalities in ST2 signaling leads to cardiac hypertrophy, fibrosis, and ventricular dysfunction. Clinically, in patients with symptomatic heart failure (HF), elevated concentrations of sST2 are strongly associated with severity of the diagnosis, and powerfully predict increased risk of complications, independent of other established or emerging biomarkers. sST2 testing has also been shown to predict onset of symptomatic HF in patients with acute myocardial infarction, while in community-based subjects, sST2 values independently predict future HF, cardiovascular disease events, and mortality.